The Latest Breaking News from Sanofi

The pharma industry is poised for robust expansion this year with rising demand and technological advancement in the sector. Hence, investors might watch fundamentally solid pharma stocks Procaps Group (PROC), Sanofi (SNY), Viatris (VTRS), Ipsen (IPSEY), and Teva Pharmaceutical Industries (TEVA) for solid gains. Read on.

The pharmaceutical industry, which experienced significant growth over the past years, is anticipated to remain buoyed, driven by the increasing prevalence of chronic diseases, advancements in medical technology, and rising healthcare awareness and expenditure. Given this backdrop, quality pharma stocks Voyager Therapeutics (VYGR), Sanofi (SNY), and Pacira BioSciences (PCRX), with…

Sanofi stock undercut its 50-day line Thursday despite Dupixent outperformance as its earnings lagged Wall Street's expectations.

Sanofi is getting into the liver disease treatment space with its $1.7 billion acquisition of biotech stock Inhibrx. But Sanofi stock toppled.

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Sanofi is hoping the exposure will help put the brand in front of prospective young talent which it has struggled to recruit.

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

Good news for Americans with diabetes as Sanofi becomes the third major insulin manufacturer to cap costs at per month, reducing financial strain and i...

A Sanofi pharmaceutical plant in the south west of France has been found to have discharged large quantities of the bromopropane neurotoxin into the atmosphere in mid-November.

Hudson sought to emulate the efficiency of a race car team that recently set the world record for quickest pit stop.

Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.